Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

HIV treatment news

Show

From To
Early Initiation of Combo Antiretrovirals Gaining Support

Evidence continues to support the initiation of combined antiretroviral therapy soon after HIV infection, researchers report. In fact, the likelihood of the CD4/CD8 ratio normalizing was almost three times greater if antiretroviral therapy was initiated within 6 months of HIV infection than if it was delayed for more than 6 months, according to John Thornhill, MD, from Imperial College London in the United Kingdom, and his team.

Published
07 November 2014
From
Medscape (requires registration)
NIH Trial Tests Very Early Anti-HIV Therapy in HIV-Infected Newborns

​A new clinical trial is exploring whether giving anti-HIV therapy soon after birth to infants who became infected with HIV in the womb leads to remission of the virus, enabling the children eventually to stop treatment for an extended time period. The trial aims to build on the case of the 'Mississippi Baby'.

Published
05 November 2014
From
National Institute of Allergy and Infectious Diseases (NIAID) press release
Researchers pinpoint exactly where each building block sits in HIV

Scientists at the European Molecular Biology Laboratory (EMBL) in Heidelberg, Germany and collaborators from Heidelberg University, in the joint Molecular Medicine Partnership Unit, have obtained the first structure of the immature form of HIV at a high enough resolution to pinpoint exactly where each building block sits in the virus. The study, published online today in Nature, reveals that the building blocks of the immature form of HIV are arranged in a surprising way.

Published
04 November 2014
From
Medical Xpress
Immune cells proposed as HIV hideout don't last in primate model

The type of immune cell called macrophages, which have been proposed as a 'sanctuary site' of HIV in the brain and other organs, and as a possible cause of HIV-related brain impairment, don't live long enough to serve as reservoirs of HIV, a study in PLoS Pathogens finds.

Published
04 November 2014
From
EATG
Efavirenz compromises hormonal contraceptive implant

The widely prescribed non-nucleoside reverse transcriptase inhibitor (NNRTI) efavirenz substantially reduces levels of the hormonal contraceptive levonorgestrel, a component of a progesterone contraceptive implant widely used in

Published
03 November 2014
By
Keith Alcorn
Do emtricitabine and lamivudine have similar virological efficacy when used in first-line HIV therapy?

First-line antiretroviral regimens containing emtricitabine have superior virological efficacy to combinations containing lamivudine when combined with tenofovir and either nevirapine or efavirenz, Dutch investigators report in the online

Published
03 November 2014
By
Michael Carter
Injectable rilpivirine shows promise in phase I trials – but may work better for anal than vaginal sex

A phase one dose-finding and safety study in humans of TMC278 LA, a long-acting, injectable formation of the antiretroviral (ARV) drug rilpivirine, found that a single

Published
01 November 2014
By
Gus Cairns
Pat Robertson, Medical Expert: 'The Towels Might Have AIDS'

On a recent episode of The 700 Club, television's premier destination for religious bigotry since 1966, Robertson advised a viewer that while the chances of contracting Ebola in Kenya are slim, travelers should beware of AIDS-ridden towels. What? Yes.

Published
31 October 2014
From
Poz
How Will Generic Drugs Affect HIV Treatment in the U.S.?

In the U.S., in that many of the antiretroviral drugs that are commonly used today are approaching their patent expirations. So we can begin to conceptualize the use of generics in the U.S. and the potential cost savings. An Interview With Treatment Action Group's Tim Horn.

Published
31 October 2014
From
The Body
Injectable cabotegravir makes progress towards human efficacy studies: doubts about injectable rilpivirine

Researchers have determined the dose of an injectable formulation of the integrase inhibitor cabotegravir (formerly GSK744) that will be taken into efficacy trials to see if it

Published
30 October 2014
By
Gus Cairns

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.